Identifying Long-Term Survival Candidates among Patients with Isolated Locoregionally Recurrent Breast Cancer: Implications of the Use of Systemic Chemotherapy
- 주제(키워드) Breast neoplasm , Neoplasm recurrence , Local , Risk factors , Survivors
- 주제(기타) Oncology
- 설명문(일반) [Kim, Byoung Hyuck; Kim, Suzy] Seoul Natl Univ, Dept Radiat Oncol, Boramae Med Ctr, Seoul Metropolitan Govt, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea; [Shin, Kyung Hwan; Chie, Eui Kyu; Kim, Jin Ho] Seoul Natl Univ, Dept Radiat Oncol, Coll Med, Seoul, South Korea; [Kim, Kyubo] Ewha Womans Univ, Dept Radiat Oncol, Coll Med, Seoul, South Korea; [Hwang, Ki-Tae; Kim, Jongjin] Seoul Natl Univ, Dept Surg, Boramae Med Ctr, Seoul Metropolitan Govt, Seoul, South Korea; [Choi, In Sil; Park, Jin Hyun] Seoul Natl Univ, Dept Internal Med, Boramae Med Ctr, Seoul Metropolitan Govt, Seoul, South Korea
- 등재 SCIE, SCOPUS, KCI등재
- OA유형 gold, Green Published
- 발행기관 KOREAN BREAST CANCER SOC
- 발행년도 2020
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000169367
- 본문언어 영어
- Published As https://dx.doi.org/10.4048/jbc.2020.23.e31
- PubMed https://pubmed.ncbi.nlm.nih.gov/32595990
초록/요약
Purpose: We aimed to investigate the clinicopathologic factors associated with distant metastasis (DM) and post-recurrence overall survival (OS) after salvage treatments for isolated locoregional recurrence (ILRR) of breast cancer and identify long-term surviving patients for providing a more personalized therapy. Methods: We analyzed 125 patients who underwent salvage local treatments for ILRR after initial curative breast surgery. Results: Fifty-two (41.6%) patients experienced secondary recurrence or disease progression, of which 20 (38.5%) experienced a secondary locoregional recurrence and 40 (76.9%) experienced DM as the first site of failure. In multivariate analysis of distant metastasis free survival (DMFS) and post-recurrence OS, the initial pN2-3 stage, a disease-free interval of < 36 months, and non-curative resection for recurrent disease were independently poor prognosticators. The score for patients stratified according to the number of risk factors increased from 0 to 3; the corresponding 5-year DMFS rates were 91.4%, 53.0%, 35.9%, and 0% and the 5-year OS rates were 97.3%, 70.4%, 32.7%, and 25.0%, respectively (p < 0.001). Systemic chemotherapy reduced DM in patients with a score of 2-3, but it did not in those with a score of 0-1. Conclusion: Our collective stratification can help with prognosis prediction for ILRR of breast cancer. Depending on the DM risk of patients, the potential combination of systemic therapy should be discussed further.
more